NeogenTC Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 17

NeogenTC General Information

Description

Developer of cancer therapies designed to provide personalized anticancer treatment. The company offers engineered tumor-infiltrating lymphocyte therapies, T cell receptor-modified T cell development, and scientific research capabilities to administer cell therapy that can target solid cancers that are difficult to treat, enabling patients with cancer and the medical research community to access personalized immunotherapy that harnesses the body's immune system to target cancer cells and advance treatment options.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 11th floor, 88 Olympic-ro 43-gil
  • Pungnap-dong, Asan Institute for Life Sciences Convergence Research Center, Songpa-gu
  • Seoul
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 11th floor, 88 Olympic-ro 43-gil
  • Pungnap-dong, Asan Institute for Life Sciences Convergence Research Center, Songpa-gu
  • Seoul
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeogenTC Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 01-Jan-2025 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 27-May-2024 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 05-Apr-2021 $13.2M $13.7M Completed Clinical Trials - Phase 1
1. Seed Round 21-Dec-2020 $455K $455K Completed Clinical Trials - Phase 1
To view NeogenTC’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NeogenTC Patents

NeogenTC Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2026506548-A Highly active transposase protein for transposon systems and its uses Pending 02-Feb-2023
EP-4663752-A1 Highly active transposase protein of transposon system, and use thereof Pending 02-Feb-2023
EP-4663752-A4 Highly active transposase protein of transposon system, and use thereof Pending 02-Feb-2023
WO-2024162830-A1 Highly active transposase protein of transposon system, and use thereof Inactive 02-Feb-2023
WO-2024151001-A1 Method and device for generating immunogenicity information using artificial intelligence technology Inactive 09-Jan-2023 G16B40/20
To view NeogenTC’s complete patent history, request access »

NeogenTC Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeogenTC Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
S&S Investment Venture Capital Minority
Arche Investment Corporate Venture Capital Minority
Bluepoint Venture Capital Minority
Cosine Investment Venture Capital Minority
Devsisters Ventures Corporate Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

NeogenTC FAQs

  • When was NeogenTC founded?

    NeogenTC was founded in 2020.

  • Where is NeogenTC headquartered?

    NeogenTC is headquartered in Seoul, South Korea.

  • What is the size of NeogenTC?

    NeogenTC has 9 total employees.

  • What industry is NeogenTC in?

    NeogenTC’s primary industry is Drug Discovery.

  • Is NeogenTC a private or public company?

    NeogenTC is a Private company.

  • What is NeogenTC’s current revenue?

    The current revenue for NeogenTC is .

  • How much funding has NeogenTC raised over time?

    NeogenTC has raised $13.7M.

  • Who are NeogenTC’s investors?

    S&S Investment, Arche Investment, Bluepoint, Cosine Investment, and Devsisters Ventures are 5 of 17 investors who have invested in NeogenTC.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process